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A B S T R A C T
Objective: To evaluate outcomes in dual nucleoside reverse transcriptase inhibitor (NRTI) pretreated
children after genotyping (GT).
Methods: Weassessed CD4 and viral load (VL) in children three years after baseline GT at the time of dual
NRTI failure. Baseline high grade resistance (HR) was deﬁned as 4 nucleoside analogue mutations
(NAMs)  Q151 M or 69 insertion complex, and low grade resistance (LR) was deﬁned as <4 NAMs.
Genotypic susceptibility scores (GSS) were determined. The current selection of antiretrovirals (ARV) was
based on physician judgment and ARV availability.
Results: Seventy-two children were enrolled, with a mean age of 9.3 years; 61% were female. Baseline
median CD4was 18%, VL was 1.7 log10 with HR 37.5%, LR 56.9% and nomutation (NR, no resistance) 5.6%.
Sixty-ﬁve (90.3%) switched ARV: 46.2% non-nucleoside reverse transcriptase inhibitor (NNRTI), 30.8%
protease inhibitor (PI), and 23.1% PI + NNRTI based highly active antiretroviral therapy (HAART). The
choice of regimen did not differ based on baseline HR, LR, and NR. The median duration from dual NRTI
therapy to HAART was 5.4 years (interquartile range (IQR) 4.0–6.9 years) and the mean (SD) duration of
current HAART regimen was 1.51 (1.78) years; both were similar between ARV groups. Five children
continued dual NRTI, two interrupted therapy. The GSS score was signiﬁcantly higher in the PI group
(3.1) vs. PI + NNRTI (2.5) vs. NNRTI (2.6) groups. Sixty-three percent of the HR group used PI or
PI + NNRTI-based HAART compared to 41% of the LR group, p = not signiﬁcant. At follow-up, median CD4
changes from baseline were +5% and VL 2.2 log10 (p < 0.001). VL <1.7 log10 was seen in 59.3% of HR,
58.5% of LR, and 50.0% of NR groups (no signiﬁcant difference). More children on PI (75%) and PI + NNRTI
(80%) based HAART had VL <50 compared to NNRTI-based HAART (50%), p = 0.003.
Conclusion: PI-based regimens showed a higher rate of undetectable VL compared with NNRTI-based
regimens. Having GT may not affect second-line treatment choices in developing countries, most likely
due to late VL failure and limited availability of PIs.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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There have been only limited studies evaluating the outcome of
genotyping (GT)-directed salvage therapy in Asian children,
especially with regard to Thai children with HIV subtype A/E
and those treated with non-protease inhibitor (PI)-based ﬁrst-line
regimens.1 Prior to 2003, most Thai children were treated withses. Published by Elsevier Ltd. All rights reserved.
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in a high incidence of NRTI resistance and virological failure.2
Despite the introduction of highly active antiretroviral therapy
(HAART) in developed countries since 1997, options for salvage
regimens for Thai children have been limited by NRTI backbone
availability and the high cost of PIs. In 2003, our group found that
almost all of the 95 dual NRTI-treated Thai children had virological
failure and NRTI mutations.2 Thereafter, antiretroviral (ARV)
regimens were switched according to genotyping results, the
judgment of the pediatrician, and ARV availability. In this studywe
report the clinical, immunological, and virological outcomes and
describe the current resistance patterns three years after initial
resistance testing.
2. Materials and methods
In 2003, 95 children who had been using dual NRTIs for at least
6 months were enrolled in a cross-sectional assessment of
genotypic resistance.2 After the baseline visit, ARV regimens were
selected according to physician judgment using genotyping, viral
load, and ARV history information, and most importantly taking
into account ARV availability. From June to December 2006, these
childrenwere recruited for a follow-up cross-sectional study at the
same two pediatric HIV referral centers: Queen Sirikit National
Institute of Child Health (QSNICH) and HIV-NAT, Chulalongkorn
Hospital, Bangkok, Thailand. The protocol was approved by the
institutional review boards of QSNICH and King Chulalongkorn
Memorial Hospital. Written informed consent was obtained from
the legal guardians before enrollment.
Zidovudine (AZT), stavudine (d4T), and didanosine (ddI) have
been provided free for children through the Thai government
access to care program since 2000; lamivudine (3TC) was provided
free shortly thereafter. In late 2003, nevirapine (NVP), efavirenz
(EFV), nelﬁnavir (NFV), indinavir (IDV), and ritonavir (RTV) became
available followed by saquinavir/ritonavir (SQV/r) and lopinavir/
ritonavir (LPV/r) one year later. The availability of PIs, however,
was initially limited to a small number of children at select HIV
referral hospitals, including our centers. This was not sufﬁcient for
all patients who needed them and second-line HAART only became
widely available in 2007.3
We deﬁned the level of ARV resistance at baseline by the
number of nucleoside analogue mutations (NAMs) detected in
2003. High-grade resistance (HR) was deﬁned by the presence of
4 NAMs and/or multiple NRTI resistancemutation (Q151 M or 69
insertion complex), regardless of the presence ofmutationM184 V.Figure 1. Study schematic. (Note: HR, high grade resistance (4 nucleoside analog mut
NAMs without Q151 M or 69 insertion complex); NR, absence of major reverse tran
transcriptase inhibitor; PI, protease inhibitor.).Low grade resistance (LR)was deﬁned as<4NAMS and nomultiple
NRTI mutation. No resistance (NR) was deﬁned by the absence of
major reverse transcriptase (RT) mutations.
In 2006, the medical and laboratory history were collected
retrospectively. At this single visit, the physical exam, CD4 count,
and determination of HIV RNA (viral load or VL) (Roche Amplicor,
version 1.5, Roche Diagnostic Systems) were performed. Children
with VL 1000 copies/ml had GT using an in-house method
validated for HIV clade A/E.4 The determination of RT and protease
(PRO) mutations was based on guidelines published by the
International AIDS Society–United States (IAS–USA) Drug Resis-
tance Mutation Group.5 Genotypic susceptibility scores were
calculated using the Stanford inferred drug resistance scores as
continuous model (cGSS). If the Stanford score was <10, cGSS was
1, or if the score was 60, cGSS was 0. However, to reﬂect partial
susceptibility to drugs in the cGSS, if the Stanford score was
between 10 and 60, the intermediate susceptibility was calculated
by (60  Stanford score)/(60  10).6 Because RTV was used as a PI
booster, it was determined as an intermediate weight of 0.5 for the
GSS model.
The deﬁnitions of preferred and alternative drug classes for
ﬁrst-line failure were based on the recommendations of the 2007
Thai guidelines for ARV therapy.7 Compliance was measured by
child and/or parent self-report to questions regarding number of
missed doses in the last 3 days and in the last 3months. Anymissed
doses during either period was considered poor adherence.
2.1. Statistical methods
Statistical analysis was performed using SAS statistical software
(SAS Institute Inc, version 9.1, Cary, NC, USA) and Stata version 10
(Statacorp, College Station, TX, USA). TheWilcoxon signed rank test
and Wilcoxon rank sum test were used to evaluate the clinical
outcomes, Centers for Disease Control and Prevention (CDC)
classiﬁcation, z-scores for weight and height, within groups and
between groups, respectively with a 2-tailed p-value of 0.05.
Comparisons of resistance and risk formutations between regimens
were performed with the Chi-square test and Fisher’s exact test.
Predictors of virological suppression were assessed using multiple
logistic regression and univariate logistic regression analysis.
3. Results
Ninety-ﬁve children on dual NRTIs were enrolled at baseline in
2003.2 The mean age was 6.6 years and 56% were female. Medianations (NAMs) and/or Q151 M, 69 insertion complex); LR, low grade resistance (<4
scriptase mutations; ARV, antiretroviral therapy; NNRTI, non-nucleoside reverse
Table 1
The choice of new antiretroviral regimen and virological outcome according to
baseline resistance pattern in 72 children
Baseline resistance
pattern at time of
dual NRTI failure
List of second line
regimens
n Overall %
VL <1.7 log10
copies/ml
HR (n=27; 37.5%) NNRTI-based HAART 8 59.3%
PI-based HAART 8
PI +NNRTI-based HAART 9
Dual NRTIs 2
LR (n=41; 56.9%) NNRTI-based HAART 19 58.5%
PI-based HAART 12
PI +NNRTI-based HAART 5
Dual NRTIs 3
Interruption 2
NR (n=4; 5.6%) NNRTI-based HAART 3 50.0%
PI +NNRTI-based HAART 1
Total (n=72; 100%) 58.3%
HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase
inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease
inhibitor; HR, high resistance (4 nucleoside analog mutations (NAMs) and/or
Q151M, 69 insertion complex); LR, low resistance (<4 NAMs without Q151M, 69
insertion complex); NR, no resistance (no NAMs, Q151M, 69 insertion complex).
Viral load suppression rates were not different between the HR, LR, and NR groups
(p=0.94). The choices of dual NRTI, NNRTI-based, PI-based, and PI +NNRTI-based
HAART did not differ between the HR, LR, and NR groups (p=0.365).
T. Bunupuradah et al. / International Journal of Infectious Diseases 14 (2010) e311–e316 e313(interquartile range (IQR)) CD4% was 16% (10–27%), VL was 4.4
log10 copies/ml (4.0–4.9), and CDC classiﬁcation ratio was
2:38:49:6 (N:A:B:C). Thirty-nine percent had HR with a median
VL of 4.5 log10 copies/ml, 56% had LR with a median VL of 4.4 log10
copies/ml, and 4% had NR with a median VL of 3.9 log10 copies/ml.
Most were taking AZT/ddI (70%), while others were taking AZT/3TC
(19%), d4T/ddI (6%), and d4T/3TC (5%).
Between June and December 2006, 72 childrenwere enrolled in
the follow-up study. Twenty-three children (24%) were not
enrolled due to: death (n = 7; ﬁve from AIDS and two from septic
shock), loss to follow-up (n = 8), and referral to provincial hospitals
(n = 8) (Figure 1). At the time of death, three children were on non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART
and four were on dual NRTIs. The last regimens on record for
children lost to follow-up were dual NRTIs (n = 4) and NNRTI
HAART (n = 4), while those who were referred were taking dual
NRTIs (n = 6), PI-based HAART (n = 1), and PI + NNRTI HAART
(n = 1). These 23 children who were not enrolled had signiﬁcantly
lower average CD4% and higher VL than those who were enrolled
(14% vs. 19%, p = 0.043; 4.7 log10 vs. 4.4 log10, p = 0.031).
Of the 72 children enrolled, mean age (SD) was 9.3 (2.7) years
and 61% were female. The resistance groups as deﬁned by baseline
resistance in 2003 were HR n = 27 (37.5%), LR n = 41 (56.9%), and
NR n = 4 (5.6%). Overall, the median CD4% was 18% and median VL
was 1.7 log10 copies/ml (58.3% had VL <1.7 log10 copies/ml). The
CDC classiﬁcation was (A:B:C) 22:39:11; 18 children (25%) had
progressed in CDC clinical classiﬁcation.
The overall median (IQR) duration from dual NRTI therapy to
HAARTwas 5.4 (4.0–6.9) years and themedian (IQR) duration from
dual NRTI therapy to HAART in the HR group was 5.4 (4.2–6.9), LR
group was 5.2 (3.8–6.9), and NR group was 6.2 (4.7–9.8) years
(p = not signiﬁcant).
Themedian (IQR) of CD4%, CD4 cell count, andVL log10 copies/ml
before switching the regimen from dual NRTI to HAART were 23%
(7–27%), 545 cells/ml (209–986), 4.4 log10 copies/ml (4.2–4.9) in the
HR group and 17% (12–25%), 535 cells/ml (337–739), 4.5 log10
copies/ml (3.8–4.9) in the LR group; this was without statistical
signiﬁcance between the two groups. The choices of HAART
according to HR, LR, and NR groups are detailed in Table 1.
3.1. Current regimens and outcomes
Sixty-ﬁve children (90.3%) were taking HAART, while ﬁve
children (6.9%) remained on dual NRTIs, and ARV was interruptedFigure 2. Proportion of children with virological suppression in each treatment
group and continuous genotypic susceptibility score. (Note: p-value comparing
viral suppression rate between NNRTI-based HAART and PI-based regimens/
PI + NNRTI containing regimen = 0.003. The PI + NNRTI group had signiﬁcantly
higher continuous genotypic susceptibility scores (cGSS) compared to the PI group
(p = 0.012) and NNRTI group (p < 0.01).).due to lipodystrophy in two (2.8%) children. The current HAART
regimenswere NNRTI-based HAART in 30 (46.2%), PI-based HAART
in 20 (30.8%), and NNRTI + PI-based HAART in 15 (23.1%) (Table 2).
The virological response in each treatment group and cGSS was
shown in Figure 2.
According to thebaseline resistancepatternsand thepreferredor
alternative second-line regimens in the 2007 Thai national
treatment guidelines,7 14 (51.9%) children with HR did not have a
fully active NRTI in their new regimen, and only eight (29.6%)
children had an RTV-boosted PI-based regimen and seven (25.9%)
had an RTV-boosted PI + NNRTI-based regimen. The remaining
children in theHRgroupwere treatedwithanNNRTI-based regimen
(eight children, 29.6%), unboosted PI-based regimen (two children,
7.4%), or dual NRTIs (two children, 7.4%). Compared to theHR group,
moreLRchildren (34children, 82.9%)had fully/partially activeNRTIs
in their new regimens, and 11 (26.8%) and four (9.8%) children had
RTV-boosted PI and RTV-boosted PI + NNRTI-based regimens,
respectively. The rest had either an NNRTI-based regimen (19
children, 46.3%), unboosted PI-based regimen (one child, 7.3%), or
dualNRTIs (three children, 7.3%). All four childrenwithNR remained
on dual NRTIs with the addition of an NNRTI (three children) or
NNRTI + PI (one child). Assignment to dual NRTIs, NNRTI, PI, or
PI + NNRTI treatment groups was not associated with resistance
level; Table 1 (p = 0.365). The percentage with virological suppres-
siondidnot differ between the threegroups: 59.3%, 58.5%, and50.0%
forHR, LR, andNRgroups, respectively (p = 0.94). Sixty-ninechildren
and/or parents answered questions aboutmissed doses in the past 3
days and 3 months. Nine percent (6/69) of children had missed at
least one ARV dose in the last 3 days and 21.7% (15/69) hadmissed a
dose in the last 3 months. There was no signiﬁcant correlation
between HAART regimens and poor adherence (p = 0.381).
Of those on HAART, 28 (43.1%) had been exposed to NNRTIs
and/or PIs during 2003–2006 that were not in their current
regimen in 2006, whichwas not signiﬁcantly different between the
three current HAART groups. Of those on NNRTI-based HAART, six
children (20%) and one child (3%) had been exposed to NNRTIs or to
both NNRTIs and PIs, respectively. In the PI-based HAART group,
seven (35%) children had been exposed to NNRTIs previously and
nine (45%) children had been exposed to both NNRTIs and PIs
previously. One child (7%) had been exposed to NNRTIs and four
(27%) children had been exposed to PIs among children taking
NNRTI + PI regimens.
T
a
b
le
2
D
e
m
o
g
ra
p
h
ic
a
n
d
tr
e
a
tm
e
n
t
ch
a
ra
ct
e
ri
st
ic
s
a
t
b
a
se
li
n
e
(2
0
0
3
)
a
n
d
cu
rr
e
n
t
v
is
it
(2
0
0
6
)
C
h
a
ra
ct
e
ri
st
ic
T
o
ta
l
(N
=
7
2
)
N
N
R
T
I-
b
a
se
d
H
A
A
R
T
(n
=
3
0
)
P
I-
b
a
se
d
H
A
A
R
T
a
(n
=
2
0
)
P
I+
N
N
R
T
I-
b
a
se
d
H
A
A
R
T
b
(n
=
1
5
)
D
u
a
l
N
R
T
Is
(n
=
5
)
In
te
rr
u
p
ti
o
n
(n
=
2
)
C
u
rr
e
n
t
fe
m
a
le
:m
a
le
,
n
(%
)
4
4
:2
8
(6
1
:3
9
)
1
9
:1
1
(6
3
:3
7
)
1
0
:1
0
(5
0
:5
0
)
9
:6
(6
0
:4
0
)
4
:1
(8
0
:2
0
)
2
:0
(1
0
0
:0
)
C
u
rr
e
n
t
m
e
a
n
a
g
e
(S
D
),
y
e
a
rs
9
.3
(2
.7
)
8
.3
(2
.3
)
1
0
.3
(2
.3
)
9
.5
(2
.5
)
1
0
(3
.8
)
1
2
(7
.9
)
C
u
rr
e
n
t
C
D
C
cl
in
ic
a
l
cl
a
ss
iﬁ
ca
ti
o
n
A
:B
:C
,
n
(%
)
2
2
(3
0
.6
):
3
9
(5
4
.2
):
1
1
(1
5
.3
)
9
(3
0
):
1
7
(5
6
.7
):
4
(1
3
.3
)
2
(1
0
):
1
3
(6
5
):
5
(2
5
)
8
(5
3
.3
):
6
(4
0
):
1
(6
.7
)
1
(2
0
):
3
(6
0
):
1
(2
0
)
2
(1
0
0
):
0
:0
B
a
se
li
n
e
m
e
d
ia
n
C
D
4
%
(I
Q
R
)
1
7
.5
(1
0
–
2
6
.5
)
2
4
(1
6
–
2
8
.5
)
7
(3
–
1
4
.8
)
2
3
(1
0
–
3
1
)
2
2
(1
6
–
2
7
.5
)
2
5
(2
2
–
2
8
)
B
a
se
li
n
e
m
e
d
ia
n
V
L
lo
g
1
0
co
p
ie
s/
m
l
(I
Q
R
)
4
.4
(4
–
4
.9
)
4
.4
(4
–
4
.8
)
4
.6
(4
.3
to
5
.1
)
4
.5
(3
.9
–
4
.9
)
4
.2
(2
.9
–
4
.5
)
3
.2
9
(2
.7
4
–
3
.8
4
)
B
a
se
li
n
e
H
R
:L
R
:N
R
,
n
(%
)
2
7
(3
7
.5
):
4
1
(5
6
.9
):
4
(5
.6
)
8
(2
6
.7
):
1
9
(6
3
.3
):
3
(1
0
)
8
(4
0
):
1
2
(6
0
):
0
9
(6
0
):
5
(3
3
.3
):
1
(6
.7
)
2
(4
0
):
3
(6
0
):
0
0
:2
(1
0
0
):
0
B
a
se
li
n
e
cG
S
S
sc
o
re
c
N
o
t
a
v
a
il
a
b
le
2
.6
(2
.3
–
2
.8
)
2
.5
(2
.5
–
3
.0
)
3
.1
(2
.9
–
3
.4
)
N
o
t
a
v
a
il
a
b
le
N
o
t
a
v
a
il
a
b
le
D
u
ra
ti
o
n
o
f
cu
rr
e
n
t
A
R
V
re
g
im
e
n
,
m
e
a
n
(S
D
)
y
e
a
rs
1
.5
1
(1
.7
8
)
1
(0
.8
2
)
1
(0
.9
)
1
(0
.7
5
)
6
.1
(2
.1
6
)
1
.2
(0
.1
1
)
A
v
e
ra
g
e
n
u
m
b
e
r
o
f
re
g
im
e
n
sw
it
ch
e
s
si
n
ce
b
a
se
li
n
e
p
ri
o
r
to
th
e
cu
rr
e
n
t
re
g
im
e
n
1
.4
3
(1
.0
7
)
1
.3
4
(0
.8
4
)
2
.3
(1
.1
7
)
1
.1
3
(0
.3
5
)
0
0
C
u
rr
e
n
t
m
e
d
ia
n
C
D
4
%
(I
Q
R
)
2
5
(2
0
.3
–
3
1
)
2
9
(2
1
.8
–
3
2
.3
)
2
3
(1
8
.3
–
2
6
.5
)
2
7
(2
4
–
3
2
)
2
6
(2
0
–
2
9
)
2
5
.5
(2
5
–
2
6
)
C
u
rr
e
n
t
m
e
d
ia
n
C
D
4
%
ch
a
n
g
e
(I
Q
R
)
fr
o
m
b
a
se
li
n
e
5
(1
.3
–
1
3
)d
3
.5
(2
–
7
)d
1
4
.5
(8
–
1
8
.8
)d
3
(–
4
to
1
7
)
4
(1
–
4
.5
)
0
.5
(–
3
to
4
)
C
u
rr
e
n
t
V
L
lo
g
1
0
co
p
ie
s/
m
l
1
.7
(1
.7
–
3
.4
)
2
(1
.7
–
4
)
1
.7
(1
.7
–
1
.8
)
1
.7
(1
.7
–
1
.7
)
3
.7
(2
.7
–
4
.1
)
4
.0
0
(3
.8
3
–
4
.1
5
)
M
e
d
ia
n
V
L
ch
a
n
g
e
(I
Q
R
)
fr
o
m
b
a
se
li
n
e
(l
o
g
1
0
co
p
ie
s/
m
l)
2
.2
(
2
.9
to
0
.9
)d
1
.7
(
2
.7
to
0
.8
)d
2
.8
(
3
.3
to
1
.6
)d
2
.8
(
3
.2
to
2
.1
)d
0
.2
(
1
.6
to
0
.6
)
0
.7
(0
.3
–
1
.0
9
)
H
A
A
R
T
,h
ig
h
ly
a
ct
iv
e
a
n
ti
re
tr
o
v
ir
a
l
th
e
ra
p
y
;
N
R
T
I,
n
u
cl
e
o
si
d
e
re
v
e
rs
e
tr
a
n
sc
ri
p
ta
se
in
h
ib
it
o
rs
;
N
N
R
T
I,
n
o
n
-n
u
cl
e
o
si
d
e
re
v
e
rs
e
tr
a
n
sc
ri
p
ta
se
in
h
ib
it
o
rs
;
P
I,
p
ro
te
a
se
in
h
ib
it
o
r;
H
R
,h
ig
h
re
si
st
a
n
ce
(
4
n
u
cl
e
o
si
d
e
a
n
a
lo
g
m
u
ta
ti
o
n
s
o
r
N
A
M
s
a
n
d
/o
r
Q
1
5
1
M
,6
9
in
se
rt
io
n
co
m
p
le
x
);
LR
,l
o
w
re
si
st
a
n
ce
(<
4
N
A
M
s
w
it
h
o
u
t
Q
1
5
1
M
,6
9
in
se
rt
io
n
co
m
p
le
x
);
N
R
,n
o
re
si
st
a
n
ce
(n
o
N
A
M
s,
Q
1
5
1
M
,6
9
in
se
rt
io
n
co
m
p
le
x
);
S
D
,s
ta
n
d
a
rd
d
e
v
ia
ti
o
n
;
C
D
C
:
C
e
n
te
rs
fo
r
D
is
e
a
se
C
o
n
tr
o
l
a
n
d
P
re
v
e
n
ti
o
n
;
IQ
R
,
in
te
rq
u
a
rt
il
e
ra
n
g
e
;
cG
S
S
,
co
n
ti
n
u
o
u
s
g
e
n
o
ty
p
ic
su
sc
e
p
ti
b
il
it
y
sc
o
re
;
A
R
V
,
a
n
ti
re
tr
o
v
ir
a
l;
V
L,
v
ir
a
l
lo
a
d
.
a
1
9
o
f
2
0
w
e
re
o
n
ri
to
n
a
v
ir
b
o
o
st
e
d
P
I-
b
a
se
d
H
A
A
R
T
.
b
1
2
o
f
1
5
w
e
re
o
n
ri
to
n
a
v
ir
b
o
o
st
e
d
P
I-
b
a
se
d
H
A
A
R
T
.
c
T
h
e
P
I+
N
N
R
T
I
g
ro
u
p
h
a
d
si
g
n
iﬁ
ca
n
tl
y
h
ig
h
e
r
cG
S
S
co
m
p
a
re
d
to
th
e
P
I
(p
=
0
.0
1
2
)
a
n
d
N
N
R
T
I
(p
<
0
.0
1
)
g
ro
u
p
s.
p
-V
a
lu
e
o
f
N
N
R
T
I-
b
a
se
d
H
A
A
R
T
to
P
I-
b
a
se
d
H
A
A
R
T
=
n
o
t
si
g
n
iﬁ
ca
n
t.
d
p
<
0
.0
0
1
w
h
e
n
co
m
p
a
re
d
to
b
a
se
li
n
e
.
T. Bunupuradah et al. / International Journal of Infectious Diseases 14 (2010) e311–e316e314Reasons for remaining on the same dual NRTIs in ﬁve children
with HR/LRwere poor adherence or tolerabilitywith HAART. Seven
children who were on double PIs or PI + NNRTI-based regimen
were not on NRTIs. The NRTIs used in 63 childrenwere 3TC (74.2%),
ddI (56.4%), AZT (41.9%), and d4T (4.8%). NVP and EFVwere used in
17 (23.6%) and 28 (38.9%) children, respectively. In 20 children
using one PI with or without NNRTI, three (15%) used unboosted PI
(NFV), while the remainder used RTV-boosted PIs: LPV/r (n = 9,
45%) and IDV/r (n = 8, 40%). Double PIs were used in 15 children
(20.8%). Combinations of PIs included IDV/LPV/RTV (40%), SQV/
LPV/RTV (33.3%), NFV/LPV/RTV (2.1%), and IDV/NFV (6.7%).
Table 2 displays the demographic and outcome data of children
according to current treatments. Overall demographics were not
signiﬁcantly different across the ﬁve groups except for the lower
baseline CD4% in the PI group and higher baseline cGSS score in the
PI + NNRTI group.
Median VL decreased by 2.2 log10 over the study period.
However, VL was undetectable in 75% of children on PI-based
regimens and 80% on PI + NNRTI regimens, whereas only 50% and 0
children on NNRTI-HAART and dual NRTIs achieved undetectable
VL (p = 0.003). Fewer children on NNRTI-based HAART than PI-
based (PI or PI + NNRTI) HAART had HIV-RNA less than 1.7 log10
copies/ml (50.0% (15/30) vs. 77.1% (27/35), p = 0.023), and this
effect remained after stratifying the treatment groups by baseline
VL 5.0 log10 in year 2003. In those treated with RTV-boosted PI-
based HAART, 77.4% (24/31) had VL <1.7 log10 copies/ml. In a
subgroup analysis, 10 of 15 children (66.7%)with a double PI-based
regimen and 15 of 30 (50%) with an NNRTI-based regimen had VL
<1.7 log10 (p = not signiﬁcant).
For all treatment regimens, the median z-scores for weight-for-
age, height-for-age, and weight-for-height decreased during the
follow-up period (0.6, p < 0.001;0.4, p < 0.001;0.2, p = 0.036,
respectively). Overall median CD4% increased from 17.5% to 25%
and median CD4 increased from 540 to 806 cells/mm3 (both
p < 0.001 compared to baseline).
In a univariate and multivariate logistic regression analysis, the
only factor predicting undetectable VL was whether the regimen
contained PIs. Children on regimens of PI or those on PI + NNRTI-
based regimens were more likely to attain virological suppression
(odds ratio 3.27, 95% conﬁdence interval 1.11–9.60; p = 0.03) than
children only treated with NNRTIs. In univariate analysis, gender,
age at starting HAART, baseline VL, CD4%, grade of resistance (HR,
LR, NR) in 2003, cGSS, and duration from dual NRTI to HAART, were
not associated with VL suppression.
3.2. Genotypic resistance in 2006 after failing the current HAART
Nineteen children (26.4%)with current VL1000 copies/ml had
GT testing in 2006. The median VL of these 19 children was 4.0
log10 copies/ml (IQR 3.5–4.4). The number (%) of children with 4
NAMs was 10/30 (33.3%) for NNRTI-based HAART, 1/15 (6.7%) for
PI + NNRTI-based HAART, and 1/5 (20%) for dual NRTIs. Q151 M, 69
insertion complex, and K65R were not detected. Of the ﬁve
children with HR in 2003, four children had HR and one child had
NR in 2006. For the 13 children with LR in 2003, seven progressed
to HR, ﬁve had LR, and one hadNR in 2006. The one childwith NR in
2003 had HR in 2006.
NNRTI resistance mutations were detected in 1/5 treated with
dual NRTIs and 11/30 (36.7%) treated with NNRTI-based HAART.
The average number of NRTI resistance mutations was 4.1 and of
NNRTI resistance mutations was 1.5. The four most common NRTI
mutations were M41L (50%), D67N (50%), K219Q (45.4%), and
T215F (41%). The three most common NNRTI mutations were
K103N (in 25% of children with NNRTI mutations), Y181C (25%),
and Y188L (25%). Nomajor proteasemutations were present in the
two children with VL >1000 copies/ml using PI-based regimens.
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After genotyping for dual NRTI failure, overall 58% of children
achieved viral suppression, and baseline resistance in 2003was not
associated with viral suppression after 3 years of follow-up. In fact,
children with HR were able to achieve undetectable viral loads
similar to those observed in the LR group, despite having limited
options for NRTI backbone. This response by thosewith HR is likely
due to switching to PI-containing regimens. Overall, children
treated with PI, particularly RTV-boosted PI, had a superior
virological outcome compared to those on NNRTI, regardless of
degree of NRTI resistance or number of fully active NRTIs. A
signiﬁcant number of children were not treated with preferred
HAART, due mainly to lack of ARV availability.
The accumulation of resistance mutations poses a challenge for
the choice of the appropriate salvage regimen. Almost 40% of our
children had multi-NRTI resistance at baseline. The virological
outcome for children on a PI-based regimen or PI + NNRTI-based
regimen was superior to non-PI regimens suggesting that an
NNRTI-based regimen without PI might not be effective enough in
late failures and that GT needs to be done early to detect early
treatment failure. The option for NRTIs for second-line therapy in
Thai children is limited even in the year 2009, since tenofovir is not
licensed for use in children younger than 18 years of age and
abacavir is too expensive in Thailand and is not included in the
government universal healthcare coverage. Additionally, the
government program mainly provides one PI (LPV/r) for children
for salvage therapy. Atazanavir/r is available for selected children
with signiﬁcant hyperlipidemia from other PI regimens. Except for
those without M184 V, few HR children had fully active NRTIs in
their new regimens. Some studies among adults have reported a
superior virological response with genotypic (GT)-directed salvage
therapy,8–10 while others have reported no beneﬁt.11 The PENTA 8
randomized trial showed that GT provided no virological beneﬁt,
although physicians were more likely to maintain children in the
GT group on at least oneNRTI from the failing regimen compared to
childrenwithout GT.12 In our study, the newHAART regimenswere
chosen by each child’s personal physician and the decision was
limited by drug cost and availability. Although we found a non-
signiﬁcant association between receiving PI-based HAART and
having HIV with HR, we were unable to determine whether GT
results inﬂuenced prescribing practices because we did not have a
control group who did not receive GT.
The Thai HIV treatment guidelines recommended using either
NNRTI-based or PI-based HAART for children who had failed dual
NRTIs.13 After assessing the resistance proﬁles in 2003, we
predicted improved outcomes with PI-based regimens due to
the higher resistance threshold of PIs.2 In 2006, children who had
PI-containing regimens had better VL suppression compared to
those who had non-PI containing regimens (75% for double/single
PI, 80% for PI + NNRTI vs. 50% for NNRTI regimen). Our overall VL
suppression rate of PI-containing regimens in 2006 was compar-
able to a prospective study of an RTV-boosted PI-based regimen in
PI-naı¨ve, NRTI/NNRTI failing Thai children.14 Over one third of
children on NNRTI-based HAART had mutations to NNRTIs and/or
4NAMS,while few on PI-based regimens hadNRTI resistance and
none had major PI mutations. This is similar to other studies
describing limited PI mutations in patients failing PI, particularly
RTV-boosted PI-based regimens.15
This study has several limitations. First, our study may have
overestimated the improvements in immunological and virolo-
gical status because 23 children who were not enrolled, due to
death, referral, and loss to follow-up, had lower CD4% and higher
VL at baseline. The small number of children in this retro-
spective study without a control arm caused difﬁculty in
interpretation. Second, the cross-sectional, retrospective natureof this study may have resulted in incomplete data collection of
ARV history. Third, the children’s new HAART regimens were
selected based on physician judgment and ARV availability
making the interpretation of usefulness of GT and the assess-
ment of outcomes difﬁcult with some biases in each group of
children. Fourth, the study does not have the power to
adequately compare outcomes of different HAART regimens.
Each ARV is individually assigned a GSS score from 0 to 1
regardless of their combined potency and different pharmaco-
kinetic proﬁle possibly resulting in an inaccurate assessment of
the new regimen’s true potency.
Despite limitations, our study is one of few to describe a
longitudinal follow-up of children who changed from dual NRTI
regimens to new HAART in a resource-constrained setting. Despite
the high prevalence of viral resistance and limitation of preferred
ARVs, about 60% had improved clinical, immunological, and
virological outcomes after switching from dual NRTIs to HAART.
Those who were on RTV-boosted PI-based regimens had the best
VL outcome regardless of baseline resistance and number of fully
active NRTIs. Genotyping may be less valuable in situations where
subsequent regimen choices are limited. Instead, having access to
RTV-boosted PI-based regimens and VL testing to detect early
virological failure may be more important in improving treatment
outcome.
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